Ascletis Completes Dosing of All Participants in Its U.S. Clinical Study Combining Adipose-Targeted, Once-Monthly Injectable Small Molecule THRβ Agonist, ASC47, and Semaglutide for the Treatment of Obesity

Core Insights - Ascletis Pharma Inc. is conducting a randomized, double-blind, placebo-controlled study (ASC47-103) to evaluate the safety, tolerability, and preliminary efficacy of ASC47 in combination with semaglutide for obesity treatment [2][5] - The study has successfully enrolled 28 participants in less than two months, indicating strong interest in new obesity treatment options [3][8] - Topline data from the study is expected to be released in the fourth quarter of 2025 [4][8] Company Overview - Ascletis Pharma Inc. is a biotechnology company focused on developing and commercializing therapeutics for metabolic diseases, utilizing proprietary platforms for drug discovery [6] - The company is listed on the Hong Kong Stock Exchange under the ticker 1672.HK [6] Study Details - The ASC47-103 study includes three cohorts receiving single doses of ASC47 (10 mg, 30 mg, and 60 mg) or placebo, along with four doses of semaglutide (0.5 mg, once weekly) [5] - ASC47 is characterized as an ultra-long-acting subcutaneously administered thyroid hormone receptor beta selective small molecule agonist, with a half-life of up to 40 days [3][5] - In preclinical studies, ASC47 demonstrated superior fat mass reduction compared to semaglutide and tirzepatide in diet-induced obese mouse models [3]